Susheela Tridandapani PhD

Susheela Tridandapani PhD
ProfessorCollege of MedicineSusheela.Tridandapani@osumc.edu
405D Davis Heart & Lung Inst. 473 W 12th Avenue Columbus OH 43210
Phone:(614) 247-6768Fax: (614) 293-4799
  • Leukemia Research

Research Description

Dr. Tridandapani's research examines the molecular mechanisms of innate immune responses to bacterial pathogens and IgG-immune complexes, particularly in the context of monoclonal antibody therapy for cancer.

Current Publications

  • Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur BRole of Cysteine-rich 61 Protein (CCN1) in Macrophage-mediated Oncolytic Herpes Simplex Virus Clearance.Mol Ther 22 1678-87 9/1/2014
  • Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JCOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.MAbs 6 749-55 5/1/2014
  • Alamuru NP, Behera S, Butchar JP, Tridandapani S, Kaimal Suraj S, Babu PP, Hasnain SE, Ehtesham NZ, Parsa KVA novel immunomodulatory function of PHLPP1: inhibition of iNOS via attenuation of STAT1 ser727 phosphorylation in mouse macrophages.J Leukoc Biol in press 1/17/2014
  • Gillette DD, Tridandapani S, Butchar JPMonocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets?Front Cell Infect Microbiol 4 18 1/1/2014
  • Knoell DL, Liu MJ, Bao S, Napolitano JR, Burris DL, Yu L, Tridandapani SZinc regulates the acute phase response and serum amyloid A production in response to sepsis through JAK-STAT3 signaling.PLoS One 9 e94934 1/1/2014
  • Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani SFcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.J Biol Chem 288 26800-9 9/13/2013
  • Jacob NK, Lapalombella R, McGourty J, Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy NGlycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs 5 723-35 9/1/2013
  • Shah P, Fatehchand K, Patel H, Fang H, Justiniano SE, Mo X, Jarjoura D, Tridandapani S, Butchar JPToll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function.J Biol Chem 288 12345-52 4/26/2013
  • Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JCComparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.J Immunol 190 2702-11 3/15/2013
  • Gillette DD, Shah PA, Cremer T, Gavrilin MA, Besecker BY, Sarkar A, Knoell DL, Cormet-Boyaka E, Wewers MD, Butchar JP, Tridandapani SAnalysis of human bronchial epithelial cell proinflammatory response to Burkholderia cenocepacia infection: inability to secrete il-1β.J Biol Chem 288 3691-5 2/8/2013
  • Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K, Shah P, Wisler J, Eubank TD, Tridandapani S, Paulaitis ME, Piper MG, Marsh CBMacrophage microvesicles induce macrophage differentiation and miR-223 transfer.Blood 121 984-95 2/7/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu